tiprankstipranks
Trending News
More News >

Dr. Reddy’s upgraded to Buy from Hold at HSBC

HSBC upgraded Dr. Reddy’s (RDY) to Buy from Hold with a price target of $16.90, up from $14.44. The firm believes semaglutide sales will help Dr. Reddy’s to return to earnings growth path within a year of launch in key markets. While a recent court order in India has restrained Dr. Reddy’s launch of semaglutide in export markets until the patent expiry of the reference brand in India in March 2026, the company will be among the first companies to launch in key markets opening up in 2026, the analyst tells investors in a research note. The firm sees a semaglutide-led earnings recovery for the company.

Confident Investing Starts Here:

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Disclaimer & Disclosure

Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.

Report an Issue